Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
At a glance
Conditions
NCT05723926
Where you'd take part
This study runs at 21 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Boston University Medical Center
Boston, Massachusettsstudy coordinator listed
Recruiting
Erlanger Medical Center
Chattanooga, Tennesseestudy coordinator listed
Recruiting
Hamilton General Hospital
Hamilton, Canada, Canadastudy coordinator listed
Recruiting
Hcfmrp-Usp
Monte Alegre, Brazilstudy coordinator listed
Not yet recruiting
HCPA
Porto Alegre, Brazilstudy coordinator listed
Not yet recruiting
Hospital de Base de Rio Preto
São José do Rio Preto, Brazilstudy coordinator listed
Not yet recruiting
Hospital Estadual Central de Vitória
Vitória, Brazilstudy coordinator listed
Not yet recruiting
Hospital São Rafael
Salvador, Brazilstudy coordinator listed
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Ashkan Shoamanesh, MD, FRCPC · PRINCIPAL_INVESTIGATOR · Population Health Research Institute, McMaster University
- Alexander P Benz, MD MSc · PRINCIPAL_INVESTIGATOR · Population Health Research Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Large vessel occlusion strokes (efficacy)44 months
assessed by MRI/CTA
- Serious device or procedure related complications (safety)44 months
Defined as any carotid filter or procedure related complication (excluding ischemic stroke) that results in death) or major disability, or that requires endovascular stenting or surgical correction.
- ISTH (International Society on Thrombosis and Haemostasis) major bleeding occurring during OAC + clopidogrel intake.44 months